An observational study in Mild Cognitive Impairment and Aging, sponsored by Yaakov Stern. Recruiting at 1 site in United States. Open to participants aged 55 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-11.
Sponsored by Yaakov Stern · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,421 studies in Cognitive Dysfunction with a site in United States — 328 open to participants now, 431 under way, 13 of them phase 3. Cognitive Dysfunction · United States.
Among the 1,421 studies in Cognitive Dysfunction with a site in United States, this one is the 153rd largest by planned enrollment of the 270 observational ones that give a count, is one of 84 that started in 2018, is one of 270 observational ones, reaches primary completion later than 152 of the 430 other live ones, and was the 526th registered.
3,881 studies on the registry are indexed under Cognitive Dysfunction; 1,121 are open to participants now.
Browse Cognitive Dysfunction studies →328 of the 1,421 studies in Cognitive Dysfunction with a site in United States are open now. Recruiting first, the newest first:
National Institute of Mental Health (NIMH) · Sites in United States
Ages 50–100 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 65+
University of Pittsburgh · Sites in United States
Ages 65+
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 50–100 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 752 Cognitive Dysfunction studies recruiting now, 362 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 55 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,421 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 126 · Phase 2 234 · Phase 3 54 · Phase 4 58
First in 1993; this study’s year is marked. 84 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 105 is below the median of 150 across 998 observational studies indexed under Cognitive Dysfunction.
Median enrollment 59 across the 1,146 interventional studies, 150 across the 270 observational. Of the 889 that completed or were terminated, 378 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
209 of 1,421 have an industry lead sponsor. The 10 most frequent:
Yaakov Stern is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Yaakov Stern has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
174 of the studies in Cognitive Dysfunction with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT06191965Phase 3Mclean HospitalMitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction | 2027-01-31 |
| NCT06950190Phase 3Ellis MedicineEvaluating Cognitive Changes on Patients in Chemotherapy (ECCPC) | 2027-02-20 |
| NCT03560960Boston UniversityMulti-Center Development of a Novel Diagnostic Test for Alzheimer's Disease | 2026-11 |
Add all 174 to your calendar (.ics) → With an account.
Among the 1,421 studies in Cognitive Dysfunction with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators aim to use the new PET radioligand, 18F-MK-6240, to detect tau pathology in cognitive healthy and mild cognitive impairment (MCI) elders. The investigators will then examine the interactions between differential tau burden and performance on cognitive tasks, functional magnetic resonance imaging (fMRI) neural activation patterns, and other cognitive and behavioral measures. By investigating these relationships, the investigators hope to understand the cognitive and behavioral outcomes of tau deposition found in specific brain regions in cognitively normal/mildly cognitively impaired adults. Furthermore, the study aims to examine how the presence of tau may contribute to the risk of subsequent cognitive decline, neurodegeneration, and dementia.
Many cognitively healthy older adults have, upon post mortem evaluations, been found to have varying amounts of neurofibrillary tangles (tau) and beta-amyloid plaque deposits, which are the hallmark brain pathologies known to be associated with Alzheimer's disease and various other dementias. While some with these pathologies may not clinically express cognitive decline or dementia in their lifetime, human post-mortem studies suggest that increasing neurofibrillary tangle density correlates with neurodegeneration and cognitive impairment.
Imaging tauopathy in-vivo provides an opportunity to examine neurocognitive correlates of differential levels of tauopathy in the brain, allowing to further qualify pre-clinical states of cognitive impairment. The investigators aim to investigate possible protective mechanisms, such as cognitive reserve, that may modulate the relationship between tauopathy and cognitive decline.
Subjects, 55-90 years old that previously received an amyloid PET scan
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants aged 55-90 that are cognitively normal or have mild cognitive impairment will receive 18F-MK-6240 to identify the presence of tau protein in the brain.
Drug: 18F-MK-6240
Results of the 18F-MK-6240 PET scan will be correlated with other observations.
Also known as: 6-[18F]Fluoro-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine
Total number of individuals with tau present
Based on the scans, the total number of subjects with identifiable tau in their scans will be measured.
Time frame: Up to 5 years
Cognition
Relation of Tau PET to measures of cognition such as memory and reasoning
Time frame: Up to 5 years
Functional imaging (fMRI)
Relation of Tau PET to imaging acquired during task performance
Time frame: Up to 5 years
Plan to share: Yes — De-identified data could be shared based on NIH regulations
Time frame: Study data will be available within 1 year
Access criteria: We will be sharing de-identified data with a consortium that is aggregating studies that have employed tau PET tracers
No publications or documents are linked to this record.
Started Jun 2018 (actual). Primary completion is estimated for Jan 2027, 103 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yaakov Stern